NYVAC CON-S env

NYVAC CON-S env is an investigational HIV-1 vaccine candidate that uses the NYVAC (New York Vaccinia virus) vector to deliver a synthetic, consensus sequence of the HIV-1 envelope glycoprotein (Env), specifically designed to induce broad immune responses against diverse HIV-1 strains. The vaccine is typically used in prime-boost regimens, often in combination with DNA or protein-based vaccines, to enhance both humoral and cellular immunity. Its mechanism involves stimulating the immune system to recognize and respond to the HIV-1 Env antigen, aiming for cross-clade antibody production and T cell responses. The primary indication is prevention of HIV infection[1][2][3][4][5].